Product Specifications

Key Features

• 24-Hour Efficacy: Boasts the longest half-life in the ARB class (approx. 24 hours), providing consistent blood pressure control with a single daily dose.

• Dual Mechanism: In addition to blocking $AT_1$ receptors, Telmisartan acts as a partial agonist of PPAR-gamma, which may offer secondary metabolic benefits regarding glucose and lipid metabolism.

• Minimal Renal Excretion: Less than 1% of the drug is excreted via the kidneys, making it a viable option for patients with varying degrees of renal impairment.

• High Tactile Integrity: Tablets are manufactured to be physically stable, though they remain hygroscopic and require storage in the original manufacturer’s bottle.

• Cardiovascular Protection: Clinically indicated to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes in high-risk patients.

Clinical Applications

• Essential Hypertension: Used alone or in combination with other antihypertensive agents to achieve target blood pressure.

• Cardiovascular Risk Reduction: Indicated for patients aged 55 and older who are unable to take ACE inhibitors and are at high risk for major CV events.

• Renal Protection: Often utilized in diabetic patients to slow the progression of nephropathy.

⚠️ Usage Note: Do not remove tablets from the bottle until the time of administration. Moisture exposure can degrade the pharmaceutical integrity of the tablet.

⚠️ Black Box Warning: FETAL TOXICITY. Discontinue as soon as pregnancy is detected. Exposure during the second and third trimesters can cause significant fetal injury or death.

⚠️ Safety: Monitor serum potassium levels regularly, especially in patients with heart failure or renal impairment, as ARBs can contribute to hyperkalemia.